Frontiers in nephrology: targeting inflammation using novel nitric oxide donors
- PMID: 17942956
- DOI: 10.1681/ASN.2007030321
Frontiers in nephrology: targeting inflammation using novel nitric oxide donors
Abstract
Chimeric molecules are single-chemical entities that possess at least two separate functions. In the design of new chimeric medicines, the two biologic actions are often designed to be synergistic and, thereby, complement each other in activating a specific target, such as a gene, a receptor, or an enzyme. In most chimeric molecules, one functionality is designed to provide a high affinity to a designated site, thereby permitting the targeting of the second functionality, which is usually nonspecific. This review focuses on the development of two classes of chimeric medicines, anti-inflammatory and diuretic chimeric agents, both of which incorporate a nitric oxide moiety into the parent pharmacophore.
Similar articles
-
Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 1-(4-methanesulfonylphenyl)-5-aryl-1H-pyrazol-3-carboxylic acids: synthesis, nitric oxide release studies and anti-inflammatory activities.Bioorg Med Chem. 2008 Jul 1;16(13):6528-34. doi: 10.1016/j.bmc.2008.05.028. Epub 2008 May 17. Bioorg Med Chem. 2008. PMID: 18513975
-
Diazen-1-ium-1,2-diolated and nitrooxyethyl nitric oxide donor ester prodrugs of anti-inflammatory (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic acids: synthesis, cyclooxygenase inhibition, and nitric oxide release studies.Bioorg Med Chem. 2008 Mar 15;16(6):3302-8. doi: 10.1016/j.bmc.2007.12.006. Epub 2007 Dec 8. Bioorg Med Chem. 2008. PMID: 18096394
-
New anti-inflammatory synthetic biflavonoid with C-C (6-6") linkage: differential effects on cyclooxygenase-2 and inducible nitric oxide synthase.Arch Pharm Res. 2009 Nov;32(11):1525-31. doi: 10.1007/s12272-009-2104-2. Arch Pharm Res. 2009. PMID: 20091265
-
Pharmacological strategies for the regulation of inducible nitric oxide synthase: neurodegenerative versus neuroprotective mechanisms.Neurochem Int. 2006 Jul;49(2):170-82. doi: 10.1016/j.neuint.2006.04.010. Epub 2006 Jun 12. Neurochem Int. 2006. PMID: 16765486 Review.
-
Nitric oxide donors: novel cancer therapeutics (review).Int J Oncol. 2008 Nov;33(5):909-27. Int J Oncol. 2008. PMID: 18949354 Review.
Cited by
-
Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions.Eur Heart J Cardiovasc Pharmacother. 2016 Apr;2(2):98-105. doi: 10.1093/ehjcvp/pvv040. Epub 2015 Dec 10. Eur Heart J Cardiovasc Pharmacother. 2016. PMID: 27340557 Free PMC article.
-
Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects.J Clin Pharmacol. 2009 Jun;49(6):668-73. doi: 10.1177/0091270009336233. Epub 2009 Apr 24. J Clin Pharmacol. 2009. PMID: 19395584 Free PMC article. Clinical Trial.
-
Designer natriuretic peptides.J Investig Med. 2009 Jan;57(1):18-21. doi: 10.2310/JIM.0b013e3181946fb2. J Investig Med. 2009. PMID: 19158603 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources